Bayer Clinches FDA Review for Kidney Drug as $2.2 Billion Ohio Plant Takes Shape
Published on 10/10/2026 at 03:10 | Editorial boerse-global.de
Bayer's share price has been grinding higher as a pair of pipeline and manufacturing developments give investors something concrete to chew on. The stock added 2.2% to trade at EUR 43.90, extending a modest recovery that has been helped along by softer crude prices and easing bond yields, according to n-tv. Germany's benchmark DAX rose 1.1% on Friday, and Bayer's advance came without any company-specific catalyst — the move rode a broader pickup in risk appetite.
The more substantive news sits in the pharmaceutical division. The US Food and Drug Administration has accepted Bayer's supplemental application for Kerendia, seeking an expanded indication for the active ingredient finerenone in adults with chronic kidney disease who do not have diabetes. The filing rests on data from the Phase III FIND-CKD trial, which enrolled 1,584 patients with non-diabetic kidney disease. Results showed that adding finerenone to standard therapy significantly slowed the loss of kidney function and cut cardiovascular-renal events.
Acceptance, however, is not approval. No official target date has been set for the agency's final verdict, leaving investors to weigh whether the data can support an unrestricted label expansion or whether further requests could stretch out the timeline.
A Wider Patient Pool With Billion-Dollar Potential
Should the US indication be broadened, Bayer would unlock meaningful additional revenue. Kerendia is currently cleared in more than 100 countries, primarily for chronic kidney disease linked to type 2 diabetes. Extending the label to non-diabetic patients would enlarge the addressable market considerably.
The company is backing its long-term US ambitions with heavy capital spending. On October 2, Bayer announced a multi-year investment of USD 2.2 billion in a new production site in New Albany, Ohio, expected to create roughly 600 permanent jobs. Active pharmaceutical ingredients are slated to be produced there from 2031, with finished products following from 2034.
Should investors sell immediately? Or is it worth buying Bayer?
Elsewhere in the network, modernization work is underway: at the Bergkamen facility, the company began decommissioning the existing primary clarifier at the wastewater treatment plant on October 5. On the leadership side, Dr. Christoph Koenen took over as Chief Medical Officer about a week ago and has led the pharmaceutical division's medical and scientific strategy since October 1.
Regulatory Wins Beyond the Kidney Franchise
The kidney filing is not the only recent regulatory milestone. On September 28, the FDA granted an accelerated review status to the investigational drug Lynkuet, aimed at easing moderate-to-severe vasomotor symptoms in women undergoing endocrine breast cancer therapy.
JPMorgan analyst Richard Vosser remains constructive on the stock, maintaining an "Overweight" rating with a price target of EUR 61. In a note dated October 1, he argued that early market expectations for the third quarter looked too high, though he anticipated little change to full-year guidance at the time. Bayer's market capitalization now stands at EUR 43.20 billion.
The Bear Case: Long Timelines, Heavy Upfront Costs
Skepticism centers on the remaining uncertainties of the approval process and the long runway before future earnings materialize. If the FDA demands extra data or writes a narrower target population into the label than hoped, the planned expansion would lose momentum. Large projects such as the Ohio plant also require substantial upfront investment, with financial returns not expected until the next decade.
Operationally, the second quarter of 2026 showed a recovery, with earnings per share of EUR 0.23 against a loss of EUR 0.20 in the prior-year period. Quarterly revenue, however, rose just 1.24% year over year to EUR 10.87 billion. Should operating growth slow while regulatory decisions drag on, market skepticism could return quickly.
Chart Level and the November 3 Print
Technically, the stock's medium-term recovery structure holds as long as it defends its 200-day moving average of EUR 43.25. A sustained break below that support would risk widening the recent correction. The next hard catalyst arrives with third-quarter 2026 results, scheduled for November 3, 2026 — a date that will show how strongly existing medicines are underpinning operating profit while the FDA process continues in the background.
Ad
Bayer Stock: New Analysis - 10 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
